PHASE 1 STUDY OF HUMANIZED 3F8 MONOCLONAL ANTIBODY (HU3F8) IN PATIENTS WITH HIGH-RISK NEUROBLASTOMA AND GD2-POSITIVE TUMORS

$2,680,415FY2012Department of DefenseDOD

Sloan-Kettering Institute For Cancer Research

Investigators